Editorials

Thrombolytic treatment

BMJ 1995; 311 doi: https://doi.org/10.1136/bmj.311.7005.582 (Published 02 September 1995) Cite this as: BMJ 1995;311:582
  1. Marc Verstraete
  1. Professor Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Campus Gasthuisberg O&N, B-3000 Leuven, Belgium

    Valuable in arterial thrombosis but of less certain value in venous thromboembolism

    Thrombolytic treatment has quickly established itself as effective, but doctors may have problems in drawing conclusions from the large number of clinical trials and anecdotal reports. Guidelines prepared by experts are therefore welcome--particularly on such a rapidly developing subject. The Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology has recently prepared new guidelines on the use of thrombolytic treatment,1 which supersede those of the American College of Cardiology and American Heart Association.2

    Unless there are clear contraindications, all patients with myocardial infarction (as diagnosed by >/= 1 mm ST elevation in two or more contiguous leads or left bundle branch block in an electrocardiogram) should receive aspirin and thrombolytic treatment with a minimum of delay. Patients diagnosed as having evolving myocardial infarction should receive …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe